Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
A Phase III, Multi-Center, Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Clinical Study to Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
Sponsor: Durect
A PHASE3 clinical study on Attention Deficit Hyperactivity Disorder, this trial is completed. The trial is conducted by Durect and has accumulated 8 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jan 2021 — Jan 2022 [monthly]
Unknown Status PHASE3
▶ Show 3 earlier versions
-
Jan 2019 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Durect
- Orient Pharma Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .